FDA Approves Lenvatinib for Treatment of Advanced Hepatocellular Cancer

(August 20, 2018)

The U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA® (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). This approval was based on results from REFLECT, where LENVIMA... Continue Reading

Cyramza Improves Survival in Poor-Prognosis Liver Cancer

(July 12, 2018)

Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at Massachusetts General Hospital presented new data at the 2018 World Congress on Gastrointestinal Cancer (WCGC) demonstrating that Cyramza (ramucirumab) significantly improves survival in a subset... Continue Reading

Cabometyx™ May Be ‘New Treatment Option’ for Liver Cancer

(February 20, 2018)

CancerConnect News: Treatment with Cabometyx (cabozantinib) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it could offer a new treatment option for this patient population. ... Continue Reading

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer

(February 15, 2018)

CancerConnect News: According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About... Continue Reading